Adverse events of unapproved drugs in Japan

The Lancet Oncology

Volumn 9, Issue 5, 2008, Pages 414-415

  Miyakoshi, Shigesaburo ^a   Kusumi, Eiji ^b   Kodama, Yuko ^b   Narimatsu, Hiroto ^b   Hamaki, Tamae ^b   Matsumura, Tomoko ^b   Kami, Masahiro ^b  

^a TORANOMON HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; NEW DRUG; THALIDOMIDE;

CANCER CHEMOTHERAPY; CERTIFICATION; CLINICAL TRIAL; DATA COLLECTION METHOD; DRUG APPROVAL; DRUG FATALITY; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; GOVERNMENT; HUMAN; INFORMATION DISSEMINATION; INTERSTITIAL PNEUMONIA; JAPAN; LETTER; LUNG DISEASE; MULTIPLE MYELOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; CONSUMER PRODUCT SAFETY; DRUG APPROVAL; DRUG LABELING; GOVERNMENT REGULATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; JAPAN; MARKETING OF HEALTH SERVICES; PATIENT EDUCATION AS TOPIC; PATIENT RIGHTS; PATIENT SELECTION; PYRAZINES;

EID: 42949162709     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70116-5     Document Type: Letter

References (5)

1. Ketsueki R. [Review process of anticancer drugs in Japan.]. Jap J Clin Hematol 47 (2006) 626-632
2. http://www.fda.gov/cder/rdmt/NDAapps93-04.htm (accessed Dec 25, 2007).
3. Tsuji K., and Tsutani K. Drug lag in the US, EU and Japan-analyses according to the licensor's nationality, biopharmaceuticals and therapeutic groups. Jap J Clin Pharmacol Therap 38 suppl (2007) S198
4. http://www.janssen.co.jp/inforest/di/vel?paf_gear_id=2200042&paf_gm= content&paf_dm=full&vid=v11&cid=cnt29610&product=vel (accessed April 8, 2008).
5. Miyakoshi S., Kami M., Yuji K., et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 107 (2006) 3492-3494